ABSTRACT Importance: The ATP-binding cassette subfamily A member 3 (ABCA3) protein plays a vital role in surfactant homeostasis. Mutations in the ABCA3 gene lead to the development of interstitial lung disease. In the most severe manifestation, mutations can lead to a fatal respiratory distress syndrome in neonates. ABCA3 belongs to the same ATP-binding cassette transporter superfamily as the cystic fibrosis transmembrane conductance regulator (CFTR), the gene that causes cystic fibrosis. Objective: To classify ABCA3 mutations in a manner similar to CFTR mutations in order to take advantage of recent advances in therapeutics. Methods: Sequence homology between the CFTR protein and the ABCA3 protein was established. The region of CFTR that is a target for the new potentiator class of drugs was of particular interest. We performed a literature search to obtain all published mutations that were thought to be disease causing. We classified these mutations using the established CFTR classification system. When possible, we drew on previous experimental classification of ABCA3 mutations. Results: Although the proteins share the same overall structure, only a 19% identity was established between CFTR and ABCA3. The CFTR therapeutic target region has a 22% homology with the corresponding ABCA3 region. Totally 233 unique protein mutations were identified. All protein mutations were classified and mapped to a schematic diagram of the ABCA3 protein.
INTRODUCTION
Surfactant, a lipoprotein rich substrate produced by type II alveolar cells, lines the airways, reducing the surface tension and preventing lower airways collapse during exhalation. Genetic mutations affecting surfactant production and metabolism result in severe respiratory disease. Mutations in the ATP-binding cassette subfamily A member 3 (ABCA3) were first recognized in 2004 as causing fatal surfactant deficiency in neonates who
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Members of the ATP-binding cassette (ABC) transporter superfamily function to allow transport across cellular membranes. Members of the ABC transporter family share structural similarities; two transmembrane regions and two ATP-binding domains (also called nucleotide binding domains). ABCA3, a 1 704 amino acid (AA) protein, is a member of the ABC super-family and is essential for lung surfactant metabolism, and therefore normal lung function.
2 Mutations in the encoding gene, ABCA3 (NM_001089.2, OMIM 601615), lead to altered ABCA3 function that, in turn, can lead to changes in surfactant composition.
3 ABCA3 appears to be necessary for the formation of lamellar bodies, which store and secrete surfactant into the alveolar space. 4 Histologically, attenuation of ABCA3 function results in changes in the lung parenchyma where the alveolar space is filled with periodic acid-Schiff (PAS) staining material as well as macrophages, as well as proliferation of type II alveolar cells. 5 Another member of the ABC transporter family, the cystic fibrosis transmembrane regulator (CFTR), is a 1 480-AA membrane protein, which, when mutated, results in cystic fibrosis. CFTR (NP_000483.3) is unique among the ABC transporter protiens, as it is the only chloride channel. This chloride channel spans epithelial membranes of exocrine tissues throughout the body, and defects in the CFTR chloride channel result in elevated sweat chloride concentration, sinopulmonary inspissation, and blocked, atretic pancreatic ducts and vas deferens. 6 Understanding the genetic defect underlying cystic fibrosis has significantly advanced the life expectancy over the past decade. 6 One of the tools available in advancing CFTR research has been the Cystic Fibrosis Mutation Database. 7 This loci database has collected and organized over 2 000 mutations. This work has led to the formation of the Clinical and Functional Translation of CFTR (CFTR2) database under the direction of the Cystic Fibrosis Foundation and Johns Hopkins School of Medicine. The database has allowed for the correlation of genetic mutations to clinical outcomes and treatments. 8 The most common of these mutations have been organized into functional classes, based on defects in transcription, cellular processing, concentration and function. 9 These classifications have helped clinicians understand and categorize defects on a molecular level and enabled the development of class-specific treatments. The most successful example of class-specific, molecular-targeted therapy in cystic fibrosis is ivacaftor, a chloride channel potentiator, which significantly improves lung function in patients afflicted with a mutation in CFTR that results in a nonfunctional chloride channels at the cell membrane. 10, 11 The medical breakthrough of ivacaftor has established the precedence for successful, mutation-specific therapy.
G i v e n t h a t A B C A 3 a n d C F T R a r e b o t h A B C transporters, and that classifying CFTR mutation has allowed significant advances in clinical care, we attempted to classify all ABCA3 mutations that have been reported in the literature. Previously, severe presentations have been found to be associated with frameshift and nonsense ABCA3 mutations, while missense mutations, splice site mutations and insertions/deletions were not associated with increased phenotypic severity. 12 Knowing that mutation type impacts phenotype, we classified the existing mutations, as this could help predict disease outcomes if the same mutations were found in other patients. However, there has been no attempt, to our knowledge, to organize the known mutations into general classes. The purpose of this study was to use the structure and the standards developed by CFTR research and apply them to reported ABCA3 mutations. First, we identified sequence homology between ABCA3 and CFTR. Then, using the CFTR classification system, we classified all the published, disease-causing ABCA3 mutations. In particular, we focused on the nucleotide binding domains of CFTR and ABCA3, as these are the sites of action of the potential therapies that could be relevant for the treatment of disease associated with mutations in ABCA3. To our knowledge, this is the first attempt to genetically classify ABCA3 mutations, and we hope that this will allow the progress of precision medicine as it pertains to disease related to ABCA3 mutations.
METHODS

Sequence comparison
To establish the homology between the ABCA3 and CFTR proteins, we aligned the complete protein sequences using NCBI Blastp. 13, 14 This aligment was performed with a standard initial BLASTP parameters. We then further refined our search by comparing specific locations within CFTR to similar locations in ABCA3 including nucleotide binding domains and Walker A and B domains.
Article selection in order to define all the published mutations
A PubMed search was performed using the terms "ABCA3" and "mutation", which generated 119 results. Broad, non-specific search terms were used in order to be more inclusive. The search was completed in November 2017, and contained only results that were available at this time. These results were manually filtered by reviewing the abstracts. Papers were finally selected that reported ABCA3 mutations that were linked to specific patients and were written in English.
Classification criteria
CFTR mutations were grouped based on functional analysis, using accepted CFTR classification (Table 1) ; class 1: defective protein synthesis, class II: abnormal protein folding and trafficking, class III: non-functional CFTR in the membrane, class IV: decreased chloride conductance and class V: reduced protein synthesis. Class VI was recently identified as having increased channel turnover. When the trafficking defect of the ΔF508 CFTR mutation was corrected and the protein was successfully transported to the cell surface, this mutated molecule was found have increased turnover. Thus ΔF508 CFTR mutation is both a class II and VI mutation. 15 In order to classify the ABCA3 mutations, published functional analyses were used to define functional effects of mutations. 4, [16] [17] [18] Of the 233 unique mutations collated, 14 had been experimentally classified. If only DNA mutations were reported, we attempted to find the protein mutation using MutationTaster. 19 When the mutations effect on the protein was unknown, misfolding was assumed to be the default protein abnormality. The mutations were also classified by their mutation type: frameshift, nonsense, missense, splice site, insertion or deletion.
Using the ABCA3 mutations that were experimentally classified by Matsumura et al 17 and the location of each ABCA3 mutation, missense mutations that had similar locations were assumed to have similar effects on protein function. Much of the classification work was an iterative process based on the experimental data that was available, the mutation type and location. For example, missense mutations in the ABCA3 extracellular domain 1 (ECD1) location were classified as Type II mutations because specific ABCA3 missense mutations in ECD1 were experimentally shown to lead to the accumulation ABCA3 protein in the endoplasmic reticulum. 17, 20 The same process was extended to mutations in extracellular domain 2 (ECD2). However, frameshift and nonsense mutations that were located in the nucleotide binding domain 1 (NBD1) were classified as Type I mutations as mutations of this type result in defective protein synthesis.
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RESULTS
Sequence homology
In order to compare specific regions, we first established the locations of conserved regions within each protein.
As both CFTR and ABCA3 are members of the ABC transporter family, albeit in different subfamilies, they share the same general structure (Figure 1 ). Both have four core domains, two transmembrane domains, and two nucleotide binding domains. The locations of the nucleotide binding domains of ABCA3 and CFTR were established using the NCBI Protein Database. 13, 14 Both the ABCA3 and CFTR nucleotide binding domains contain Walker A and Walker B motifs, which are conserved motifs commonly found in nucleotide binding proteins. 21 However, two major differences were identified: ABCA3 contains two extracellular domains, while CFTR contains an R domain, which plays an essential role in channel gating.
We identified the location of conserved domains within ABCA3 and CFTR. NBD1 of ABCA3 spans from AA 467 to 925. This is located between the end of the first transmembrane region (TM1) to the start of the second transmembrane region (TM2). When the complete protein sequences of ABCA3 and CFTR are aligned using NCBI Blastp, there is 19% identity shared between CFTR and ABCA3. 13 Between the NBD1 domain of each molecule, there is a 22% shared identity, while there is no significant similarity between NBD2 of ABCA3 and CFTR. To further refine the alignment, we compared the region between the start of the CFTR Walker A motif to the end of the Walker B motif in NBD1 against the corresponding region in ABCA3 and found that these regions shared 23% identity. This area is the highest area of sequence homology, which may have clinical implications as this area is targeted by the CFTR modulators (ivacaftor).
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Mutation classification
A PubMed search was performed using the terms "ABCA3" and "mutation". The search was completed in Novemeber of 2017, and 119 papers were identified. All 119 papers had their abstracts reviewed and papers were selected for inclusion when the ABCA3 mutations were linked to specific patients and were written in English. Fifty nine papers were reviewed in full. Of those 59 papers, 10 were not subject to further analysis. The reasons for excluding papers ranged from not containing patients with any genetic mutation, to only containing synonymous non-disease causing mutations. Twelve of the papers contained data that was also reported in Wambach et al. 12 For ease of access, and to avoid duplications, the data that was reported in the supplement of Wambach et al. was incorporated.
12 Supplement 1 contains a full list of papers, including notation on why specific papers were not included. In total, mutations obtained from 292 patients were incorporated with 233 unique protein changes. Eighteen unique DNA mutations were identified that did not result in protein changes, as these mutations were located in introns or promoter regions. Of these mutations, the most common type of mutation was missense mutations, although nonsense, frameshift, splice site mutations, insertions, and deletions were reported (Table 2) . Whenever possible, experimentally-determined outcomes were used to classify ABCA3 mutations (Table 3) . Typically, frameshift or nonsense mutations resulted in abnormal protein synthesis and would be classified as a Type I (CFTR) mutations. Matsumura et al 17 found that mutations in the extracellular domains (L101P and L982P) altered intracellular targeting of ABCA3. This finding is in accordance with the assumed role of these domains in intracellular trafficking. Thus missense mutations in these domains were classified as Type II (CFTR) mutations (Figure 2 ). Also the 4 mutations found in the NBD2 (Ins1518fs, L1553P, L1580P and Q1591P) were classified as Type II (CFTR) mutations as 3 of the mutations (Ins1518fs, L1553P, and Q1591P) had functional data that showed altered protein intracellular trafficking. As an exception to the above classification, the L1580P mutation altered ATP hydrolysis (a marker of ABCA3 function). L1580P mutation is located in the N-terminal region. Due to the role of the N-terminal in directing proteins to the appropriate cell compartments, we proposed that missense mutations in the N-Terminal would lead into abnormal intracellular localization and therefore classified them accordingly as Type II (CFTR) mutations. The L1580P was classified as Type II (CFTR) mutation as it altered protein trafficking.
Other mutations of ABCA3 caused decreased ATP hydrolysis activity and had normal intracellular trafficking. 16, 17 Based on the experimental data of Matsumura et al 17 , a missense mutation in the NBD1 (N568D) significantly decreased ATP hydrolysis activity would be classified as a type III mutations in the CFTR classification system as final cellular location is correct and function is abolished. Thus this mutation and missense mutations in the NBD1 region were classified as Type III (CFTR) mutations (Figure 2) . A recent paper by Wambach et. al confirmed this determination.
18 That group described a mutation in the NBD1 domain, p.R1474W, that was found to have "normal trafficking and protein processing, but decreased ATPase activity." This mutation would be correctly determined to be a Type III (CFTR) mutation using experimental data from Matsumura et al. 16, 17 Missense mutation in the transmembrane region in CFTR are associated with reduced or absent chloride conductance and are generally classified as a Type III or IV mutation. 9 In a milder phenotype of the ABCA3 related disease, Matsumura et al found that a mutation in the TM2 (T1114) was associated with reduced lipid transport. 16 We classified missense mutations in the transmembrane domains as Type IV (CFTR) mutations as they seem to be associated with a milder phenotype as some transport was preserved. Some of these mutations could fall into the CFTR Type III group if ABCA3 function was abolished.
We did focus on mutations on the area between Walker A motif and Walker B motif in NBD1 as this area is targeted by the CFTR modulators. 10 Only two mutations (L579P and L627H) were identified in this area.
DISCUSSION
Complete classification of ABCA3 mutations is important in order to take advantage of therapeutics under 950  900  850  800  750  700  650  600  550  500  450  400  350  300  250  200  150  100  50   P264R  L269dup  R280C, R280H  R288K  E292V  R295C  L303V  A307V  W308R  L326R  S341N  S359del  S356Y  N372_A376dup  G378R   P933L  L941P  P969S  A1107T, A1107V  V1120F  T1114A, T1114M  F1115L  S1116F  E1122K  Q1131R  W1142R  W1148X  I1193M   N412D  A414P, A414T  I432_R435delinsHL  L437P  P440G  G454_L458dup  L462R   F1203del  1203_1204del  G1221S  M1227R  L1238_E1239insGG  L1252P  P1253S  H1255Q  S1262G  R1271Q  G1302E  G1314R  E1325K (C) Type III Mutations development for other genetic diseases, such as cystic fibrosis. It is also important to understand the degree of homology when using another disease as a guide. Overall, the 19% overlap in identity between CFTR and ABCA3 is not impressive. However, between the NBD1 domain of each molecule there is a 22% shared identity; this was the highest area of genetic overlap. We focused on this area because it is the site of action for the potentiator class of cystic fibrosis drugs such as ivacaftor. 11, 22 Potentiators are a class of drugs that are designed to increase the time that the CFTR channel remains open when it is in the membrane.
11 They are approved to treat cystic fibrosis patients with the G551D mutation, which is a mutation that falls between the Walker A and Walker B motifs of the NBD1 of CFTR protein. G551D is the most prevalent Type III missense mutation, being found in 4% to 5% of people with cystic fibrosis. Potentiators are effective in treating G551D, because, as a Type III mutation, the CFTR protein localizes to the membrane, but is nonfunctional due to defects in the binding and the hydrolysis of ATP. Potentiators could potentially be used to treat ABCA3 mutations where they could increase the length of time that the channels are open, which could in turn aid phospholipid transport into the lamellar bodies. However, not enough is known about the role ABCA3 in surfactant homeostasis to know if keeping the channels open would have the desired effect. Furthermore, it is not clear that 23% sequence homology between this domain in CFTR and ABCA3 would be enough to successfully use CFTRdirected potentiators in ABCA3 disease.
Not only was the sequence homology of CFTR and ABCA3 in the region low, we only found 2 ABCA3 mutations (L579P and L627H) that fell in between the Walker A and B regions and were classified as a Type III mutations using the CFTR classification scheme. Both the L579P and L627H mutations were found in a patients who also carried a Type I frameshift mutation.
12 At this time it is difficult to conclude that CFTR-directed potentiators could target the ABCA3 mutations L579P and L627H like these drugs target G551D in CFTR. As a result, more research is needed on mutations in this region.
Using CFTR classification as a paradigm has it limitations. As previously stated, whenever possible experimentally determined information about the mutations and their effects was used to determine classification. However, of the 233 unique mutations, only 14 had experimentally determined functional classification (5.9% of the mutations). Therefore, it is important to note that most classifications were presumptive. Detailed understanding of the effects of ABCA3 mutations on protein processing is needed, and has important implications for patient care. As more research on the impact of specific mutations becomes available, this classification system may require modification. However, this system to classifying ABCA3 mutations will set a framework upon which additional data can be set.
The classification of ABCA3 mutation types will facilitate further research. The data collected here represents what we believe to be the full extent of known pathogenic mutations in ABCA3. Previous papers have shown that in the case of frameshift and nonsense mutations, the type of mutation has a direct effect on the disease severity.
12 This newly described classification system could be used to further evaluate disease severity and differences in patient survival. Additionally, this new mutation classification may facilitate identification of novel therapeutics for ABCA3-related lung disease. In summary, this dataset represents an initial step in the organization and classification of ABCA3 mutations that will likely lead to clinically valuable insights and treatments.
